# A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

> **NCT01264367** · PHASE4 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 60 (estimated)

## Conditions studied

- HBeAg(+) Chronic Hepatitis B

## Interventions

- **DRUG:** Clevudine
- **DRUG:** Clevudine + Peg-interferon

## Key facts

- **NCT ID:** NCT01264367
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-08
- **Final completion:** 2014-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264367, "A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01264367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*